ReviewJournal of biomedical science2018
Dengue virus non-structural protein 1: a pathogenic factor, therapeutic target, and vaccine candidate.
Review in Journal of biomedical science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it, 128 citations in OpenAlex.
- COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning.Frontiers in immunology · 2020Pooled it
- Targeting Dengue Viral Proteins with Eco-Friendly Nanotechnology: A Promising Path for Antiviral Research.Viruses · 2026Review
- Identification and validation of natural dengue virus NS1 inhibitors with promising antiviral potential.Molecular diversity · 2026Article
- CLEC5A/TLR2 bispecific antibody suppresses dengue virus-induced pro-inflammatory cytokines production from macrophages.Journal of biomedical science · 2026Article
- Roles of non-structural protein 1 in dengue virus replication and immunomodulation in vivo.The Journal of veterinary medical science · 2026Article
- Cellular Biology: Virus-Host Interactions and RNA Structure and Function.Current topics in microbiology and immunology · 2026Review
- Role of Cellular Mechanisms in Dengue Pathogenesis: Focus on Immune Cells Interactions.Combinatorial chemistry & high throughput screening · 2026Review
- Targeting dengue through mucosal vaccination: the potential of NS1 and bacterial spore-based delivery platforms.Frontiers in immunology · 2026Review
- Profiling an Enhanced IL-6 Expression Distinguishes Host Susceptibility to Primary and Secondary Infections of the Dengue Virus in an Ex Vivo Whole-Blood Coculture Model.Journal of tropical medicine · 2026Article
- Structure guided design and molecular modelling of a novel peptide-SWCNT biosensor targeting NS1 dengue virus.RSC advances · 2025Article
- Anti-Nonstructural Protein 1 Antibody Kinetics and Their Association With Disease Severity in Pediatric Dengue.Open forum infectious diseases · 2025Article
- Pharmacological Evaluation of active compounds in papaya associated with thrombocytopenia inhibition in dengue patients through in silico approaches.Scientific reports · 2025Article
- Repurposing of FDA-approved drugs against oligomerization domain of dengue virus NS1 protein: a computational approach.Molecular diversity · 2025Article
- Nanobody-Based Lateral Flow Assay for Rapid Zika Virus Detection.ACS synthetic biology · 2025Article
- Virus-Induced Pathogenic Antibodies: Lessons from Long COVID and Dengue Hemorrhage Fever.International journal of molecular sciences · 2025Review
- Dengue Virus Infection: Immune Response and Therapeutic Targets.The American journal of tropical medicine and hygiene · 2025Review
- Article
- Article
- Dengue virus NS1 hits hard at the barrier integrity of human cerebral microvascular endothelial cells via cellular microRNA dysregulations.Tissue barriers · 2025Article
- In-host modeling of dengue virus and non-structural protein 1 and the effects of ivermectin in patients with acute dengue fever.CPT: pharmacometrics & systems pharmacology · 2024Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Dengue virus (DENV) infection is the most common mosquito-transmitted viral infection. DENV infection can cause mild dengue fever or severe dengue hemorrhagic fever (DHF)/dengue shock syndrome (DSS). Hemorrhage and vascular leakage are two characteristic symptoms of DHF/DSS. However, due to the limited understanding of dengue pathogenesis, no satisfactory therapies to treat nor vaccine to prevent dengue infection are available, and the mortality of DHF/DSS is still high. DENV nonstructural protein 1 (NS1), which can be secreted in patients' sera, has been used as an early diagnostic marker for dengue infection for many years. However, the roles of NS1 in dengue-induced vascular leakage were described only recently. In this article, the pathogenic roles of DENV NS1 in hemorrhage and vascular leakage are reviewed, and the possibility of using NS1 as a therapeutic target and vaccine candidate is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.